Cerecin

Cerecin is a biopharmaceutical company focused on discovering and developing drugs for the treatment and prevention of brain diseases. Its development programs leverage its expertise in lipid science to explore the potential therapeutic benefits of ketogenic drugs. Last year, the company received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for its lead investigational compound, Tricaprilin, for the treatment of infantile spasms. Subsequently, Cerecin initiated a pilot study to evaluate the safety, tolerability, and efficacy of Tricaprilin in infantile spasms and also commenced a Phase 2 study for migraine prevention.